ABOS: the cashflow

MyFinsight

The latest financial statement is for the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-26,451	-69,746
Depreciation	15	31
Stock-based compensation expense	2,461	4,972
Amortization of premiums and accretion of discounts on marketable securities, net	275	644
Change in fair value of embedded derivatives	-440	150
Amortization of right-of-use asset	32	61
Realized gain on marketable securities	14	3
Noncash interest expense	329	613
Other noncash expense	0	-
Prepaid expenses and other current assets	509	-1,714
Other long-term assets	-24	-18
Accounts payable	-1,421	-3,545
Accrued clinical trial expenses	-1,224	-4,236
Accrued expenses and other liabilities	-3,896	4,962
Finance lease liability	0	0
Net cash used in operating activities	-30,489	-65,953
Purchases of marketable securities	0	38,056
Proceeds from maturities and sales of marketable securities	40,511	105,316
Purchases of property and equipment	0	88
Net cash provided by investing activities	40,511	67,172
Proceeds from issuance of common stock, net of issuance costs	0	0
Proceeds from exercise of stock options	0	37
Payment for financing lease	0	0
Payments for deferred offering costs	0	0
Repurchase of common shares to pay employee withholding taxes	0	73
Net cash provided by (used in) financing activities	0	-36
Net change in cash and cash equivalents and restricted cash	10,022	1,183
Cash and cash equivalents at beginning of period	35,859	-
Cash and cash equivalents at end of period	47,064	-

Unit: Thousand (K) dollars